Stryker Corporation $SYK Shares Bought by Cibc World Market Inc.

Cibc World Market Inc. lifted its stake in Stryker Corporation (NYSE:SYK) by 11.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 157,822 shares of the medical technology company’s stock after acquiring an additional 16,790 shares during the quarter. Cibc World Market Inc.’s holdings in Stryker were worth $55,470,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Godfrey Financial Associates Inc. acquired a new position in Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the third quarter valued at approximately $27,000. Strive Asset Management LLC purchased a new stake in shares of Stryker during the third quarter valued at approximately $30,000. CGC Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter worth $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker in the third quarter valued at $34,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Up 2.0%

NYSE SYK opened at $300.82 on Friday. The company has a market capitalization of $115.32 billion, a price-to-earnings ratio of 34.82, a price-to-earnings-growth ratio of 1.86 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company’s fifty day moving average price is $318.86 and its two-hundred day moving average price is $346.14.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the company posted $2.84 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last quarter. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Truist Financial restated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. BTIG Research cut their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.